Drugs / Azeliragon
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06831526 | Nov 2025 → Feb 2029 expected | glioblastoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT07092215 | Jun → Jul 2025 | — | Stefan Heber | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06724926 | Feb 2025 → Jan 2027 expected | high grade astrocytic tumor, neoplastic meningitis | NYU Langone Health | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05773664 | Nov 2024 | glioblastoma | City of Hope Medical Center | Withdrawn | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05789589 | Nov 2023 → Mar 2027 | metastatic malignant neoplasm in the brain | Baptist Health South Florida | Suspended | No outcome recorded |
| Phase 1/2 | NCT05635734 | Sep 2023 → Apr 2026 | glioblastoma | Cantex Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT05256745 | Jun 2023 → Dec 2026 expected | breast cancer, subjective cognitive decline | Georgetown University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05766748 | Jun 2023 → Feb 2025 | malignant pancreatic neoplasm | Cantex Pharmaceuticals | Unknown | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07694089 | Oct 2026 → Aug 2029 expected | high grade astrocytic tumor | Akshitkumar MIstry | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05986851 | Sep 2023 → Sep 2026 expected | glioblastoma | Cantex Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03980730 | Jun 2019 → Dec 2020 | Alzheimer disease | vTv Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT00566397 | Dec 2007 → Dec 2010 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00141661 | Oct 2005 → Jun 2006 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05815485 | May 2023 → Apr 2026 overdue | COVID-19 | The University of Texas Medical Branch, Galveston | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02916056 | Dec 2016 → Jun 2018 | Alzheimer disease | vTv Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT02080364 | Apr 2015 → Jun 2018 | Alzheimer disease | vTv Therapeutics | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00287183 Comparator | Feb 2006 → Aug 2009 | diabetic kidney disease | Pfizer | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Azeliragon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02916056 ↗ |
| Known as | PF 04494700 | “A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants...” NCT00566397 ↗ |
| Known as | TTP448 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989929 ↗ |
| Known as | TTP488 | “A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants...” NCT00566397 ↗ |
| Action | Inhibit | “Moreover, these alterations can be reversed by the RAGE inhibitor, Azeliragon which is in a phase I/II clinical trial NCT05635734.” PMID 39744679 ↗ Jan 20251“Advanced glycosylation end product-specific receptor antagonist” CHEMBL3989929 ↗ |
| Modality | Small molecule | — CHEMBL3989929 ↗ |
| Route | Oral | “Orally-Administered PF-04494700” NCT00141661 ↗ |
| Target | AGER | “Advanced glycosylation end product-specific receptor antagonist” CHEMBL3989929 ↗ |